ASRT (assertiotx.com) Market Value to Book Value Ratio
Assertio Holdings, Inc. (ASRT) is stabilizing its portfolio of brain-related medications, leveraging acquired assets to maintain cash flow at 2.01, which mitigates external crises. However, the business faces threats from low-cost generics and debt pressure. Historical price action reflects the issuer's market volatility. Additionally, patent expirations and potential copyright litigation are constraining profits.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ASRT_-_Assertio-Holdings-Inc._-_Capitalization-to-Book-Value-Ratio "ASRT Assertio Therapeutics Market Capitalization to Book Value Ratio (07/04/2022 - 06/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Assertio Holdings, Inc. (ASRT)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Assertio Holdings - ASRT
This ratio is calculated by dividing the total market capitalization of all shares by the amount of equity. The stability of this ratio confirms the business's maturity phase, signaling either reliability or a lack of growth drivers. For Assertio Holdings, Inc. (ASRT), the efficiency of logistics and drug inventory management directly impacts the value of net assets. Analyzing the trend of the market-to-book ratio allows for an assessment of the market premium over the company's tangible resources.
Direct competitors
BIIB - Market Cap to Net Assets Ratio|NBIX (neurocrine.com) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|AMLX (Amylyx Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio TRVI|PRAX (Praxis Precision Medicines, Inc.) - Market Value to Book Value Ratio|Market Capitalization to Book Value AVXL (Anavex)|Market Value to Book Value Ratio CBLL|Market Capitalization to Book Value Prothena PRTA|ALEC (Alector Therapeutics) - Market Capitalization to Book Value Ratio|ANNX: Market-to-Book Ratio|Market Value to Book Value Ratio omeros.com OMER|Market Value to Book Value Neurogene Inc|AC Immune Corp (ACIU) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple Voyager Corp|NMRA (Neumora Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value SCLX (scilexholding.com)|TVGN: Market Value to Book Value Ratio|ACOG - Market-to-Book Ratio|Market Cap to Net Assets Ratio Cognition Therapeutics, Inc. (CGTX)|IKT - Market Value to Book Value|Market Capitalization to Book Value Ratio Cassava Sciences, Inc. SAVA|COYA (Coya Therapeutics) - Market Value to Book Value|Market Value to Book Value Ratio VTGN (VistaGen Therapeutics, Inc.)|Market-to-Book Ratio OVID|Market Value to Book Value Ratio Acumen Pharma (ABOS)|Market Value to Book Value Ratio CervoMed Corporation (CRVO)|ATHE - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio Clene Inc CLNN|Market Capitalization to Book Value Ratio PEPG (PepGen Corp)|JUNS: Market Capitalization to Book Value|Market Value to Book Value Ratio Relmada|Annovis Bio Corporation (ANVS) - Capitalization to Book Value Ratio|Grace Therapeutics Inc - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio AIFF|KLTO (Klotho Neurosciences Inc) - Market Value to Book Value Ratio|Market Capitalization to Book Value neurosense-tx.com NRSN|Market Cap to Net Assets Ratio Reviva Pharmaceuticals Holdings|Market Value to Book Value MetaVia Inc. MTVA|Market Capitalization to Book Value Ratio NRXS (NeurAxis, Inc.)|HSDT: Market Capitalization to Book Value|Market Value to Book Value Ratio passagebio.com|Neuphoria Therapeutics (NEUP) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio NERV|Market Cap to Net Assets Ratio Athira Pharma Corp (ATHA)|ADXN (Addex Therapeutics) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value alzamend.com (ALZN)|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Protagenic Therapeutics Inc. - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio KTTA (Pasithea)|CRGT: Market Capitalization to Book Value|Market Value to Book Value Ratio Avenue Therapeutics ATXI|Market Value to Book Value brainstorm-cell.com|Cara Therapeutics (CARA) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple CHRO|Market Value to Book Value Ratio Eliem Therapeutics ELYM|Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|LBPH: Market Capitalization to Book Value Ratio|MRNS - Market-to-Book Ratio|NKGen Biotech - Market Cap to Net Assets Ratio|NRBO: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Sage Therapeutics, Inc SAGE|SNPX (Synaptogenix, Inc) - Market Value to Book Value|Market Value to Book Value Ratio TRVN (Trevena, Inc.)|Market-to-Book Ratio Vigil Neuro|Market Capitalization to Book Value Ratio WENA|Market Capitalization to Book Value Ratio CERE (Cerevel Therapeutics Inc)